This MRK purchase is interesting and I have to admit that it is not what I would have expected, unless it's a relatively cheap deal for the IP and expertise.
Is there any concern from an INCY standpoint of IOmet having dual IDO/TDO inhibitors? Presumably MRK could favor these way down the road over the INCY drug, which I believe is just an IDO inhibitor. Any more guidance if it's more beneficial to inhibit both targets rather than IDO alone? Guessing just way too early to know.